Telik is conducting clinical trials with TELINTRA® (Ezatiostat HCl, TLK199). TELINTRA® is a small molecule product candidate designed to stimulate the production of blood cells in the bone marrow. Many conditions are characterized by depleted bone marrow, including myelodysplastic syndrome (MDS), a form of pre-leukemia in which the bone marrow produces insufficient levels of one or more of the 3 major blood elements (white blood cells, red blood cells and platelets). In addition to MDS, we are testing TELINTRA® in other forms of blood disorders like severe chronic neutropenia (SCN).

Additional information on MDS, please visit: http://www.mds-foundation.org/ or http://www.leukemia-lymphoma.org/all_page.adp?item_id=55442

Additional information on SCN, please visit: http://neutropenianet.org/ or http://www.neutropenia.ca/

Ongoing Clinical Trials

TELINTRA® Tablets (Ezatiostat HCl, TLK199)

Phase 2 Trial in Myelodysplastic Syndrome

Phase 2 Trial in Severe Chronic Neutropenia

Phase 1 Combination Trial with Revlimid in Myelodysplastic Syndrome

TELCYTA® (canfosfamide, TLK286)

Phase 2 trial using TELCYTA® in MCL, DLBCL & MM

For further information on ongoing trials, please see http://www.clinicaltrials.gov

Physicians and patients seeking additional information on may contact clinicaltrials@telik.com.

Completed Clinical Trials

TELINTRA®

Phase 1 Trial using TELINTRA® tablets in MDS

Phase 1-2 Trial using liposomal TELINTRA® in MDS

TELCYTA®

TELCYTA® (canfosfamide, TLK286) has been in multiple Phase 2 and Phase 3 trials in advanced cancer patients. TELCYTA® has shown clinical activity in some cancer types with a good safety profile. Additional studies will need to be completed prior to a potential regulatory submission and the company is currently pursuing corporate partners to help in the further development of TELCYTA® .

Completed Phase 3 Trials

ASSIST-5, TELCYTA® + Doxil in advanced ovarian cancer

ASSIST-3, TELCYTA® + Carboplatin in advanced ovarian cancer

ASSIST-2, TELCYTA® A single agent in advanced non-small cell lung cancer

ASSIST-1, TELCYTA® single agent in advanced ovarian cancer

Selected Phase 2 Trials include

TELCYTA® in combination with carboplatin and paclitaxel as first-line therapy in locally advanced or metastatic non-small cell lung cancer

TELCYTA® in combination with carboplatin in recurrent ovarian cancer

TELCYTA® in combination with liposomal doxorubicin in platinum-refractory or platinum-resistant ovarian cancer

TELCYTA® in combination with cisplatin as first-line therapy in locally advanced or metastatic non-small cell lung cancer

TELCYTA® in combination with docetaxel in platinum-resistant non-small cell lung cancer